Cart
sales@molnova.com
CC-99677
CAS No. 1887069-10-4
CC-99677( —— )
Catalog No. M35108 CAS No. 1887069-10-4
CC-99677 (Gamcemetinib) is a selectively targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune diseases that translates biochemical potency into cellular potency as demonstrated by potent inhibition of heat shock protein 27 (HSP1) phosphorylation in LPS-activated monocyte THP-27 cells via a nucleophilic aromatic substitution (SNAr) mechanism.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 250 | In Stock |
|
| 10MG | 432 | In Stock |
|
| 25MG | 753 | In Stock |
|
| 50MG | 995 | In Stock |
|
| 100MG | 1386 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCC-99677
-
NoteResearch use only, not for human use.
-
Brief DescriptionCC-99677 (Gamcemetinib) is a selectively targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune diseases that translates biochemical potency into cellular potency as demonstrated by potent inhibition of heat shock protein 27 (HSP1) phosphorylation in LPS-activated monocyte THP-27 cells via a nucleophilic aromatic substitution (SNAr) mechanism.
-
DescriptionGamcemetinib (CC-99677) is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM). Gamcemetinib is extracted from patent WO2020236636, compound 1.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
RecptorMAPK | HSP
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1887069-10-4
-
Formula Weight469.94
-
Molecular FormulaC22H20ClN5O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 37.5 mg/mL (79.80 mM; Ultrasonic (<60°C)
-
SMILESCCOCc1cnc(Cl)nc1Oc1ccc2c3c4NC[C@@H](C)NC(=O)c4sc3ccc2n1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. WO2020236636
molnova catalog
related products
-
methyl 5-(3,4-dimeth...
methyl 5-(3,4-dimethoxyphenyl)isoxazole-3-carboxylate targets MAPK.
-
SD-06
SD-06 is a p38 MAP kinase inhibitor, inhibits p38α with IC50 of 170 nM and inhibits LPS-stimulated TNF-release in rats.
-
JNJ-49095397
JNJ-49095397 (RV-568) is a specific narrow-spectrum kinase inhibitor that inhibits a selected set of kinases involved in COPD inflammation with IC50 of 5, 40 and 52 nM for p38α, p38γ and HCK, respectively.
